Description
Pharma Marketing & Industry
No Conferences Found
Content
Many countries have measures in place to limit advertising by pharmaceutical companies.
Pharmaceutical company spending on marketing far exceeds that of its research budget. In Canada, $1.7 billion was spent in 2004 to market drugs to physicians; in the United States, $21 billion was spent in 2002. In 2005, money spent on pharmaceutical marketing in the United States was estimated at $29.9 billion with one estimate as high as $57 billion. When the U.S. numbers are broken down, 56% was free samples, 25% was pharmaceutical sales representative "detailing" (promoting drugs directly to) physicians, and 12.5% was direct to user advertising, 4% on detailing to hospitals, and 2% on journal ads. There is some evidence that marketing practices can negatively affect both patients and the health care profession.
Marketing to health-care providers takes three main forms: activity by pharmaceutical sales representatives, provision of drug samples, and sponsoring continuing medical education (CME). The use of gifts, including pens and coffee mugs embossed with pharmaceutical product names, has been prohibited by PHRMA ethics guidelines since 2008. Of the 237,000 medical sites representing 680,000 physicians surveyed in SK&A's 2010 Physician Access survey, half said they prefer or require an appointment to see a rep (up from 38.5% preferring or requiring an appointment in 2008), while 23% won't see reps at all, according to the survey data. Practices owned by hospitals or health systems are tougher to get into than private practices, since appointments have to go through headquarters, the survey found. 13.3% of offices with just one or two doctors won't see representatives, compared with a no-see rate of 42% at offices with 10 or more doctors. The most accessible physicians for promotional purposes are allergists/immunologists – only 4.2% won't see reps at all – followed by orthopedic specialists (5.1%) and diabetes specialists (7.6%). Diagnostic radiologists are the most rigid about allowing details – 92.1% won't see reps – followed by pathologists and neuro radiologists, at 92.1% and 91.8%, respectively.
E-detailing is widely used to reach "no see physicians"; approximately 23% of primary care physicians and 28% of specialists prefer computer-based edetailing, according to survey findings reported in the 25 April 2011, edition of American Medical News (AMNews), published by the American Medical Association (AMA).
Market Analysis:
Pharmaceutical Company spending on marketing exceeds that spent on research. In 2004 in Canada $1.7 billion a year was spent marketing drugs to physicians and in the United States $21 billion were spent in 2002. In 2005 money spent on pharmaceutical marketing in the United States was estimated at $29.9 billion with one estimate as high as $57 billion. When the US numbers are broken down 56% was free samples, 25% was detailing of physicians, 12.5% was direct to users advertising, 4% on hospital detailing, and 2% on journal ads. In the United States approximately $20 billion could be saved if generics were used instead of equivalent brand name products.
Although pharmaceutical companies have made large investments in marketing their products, overall promotional spending has been decreasing over the last few years, and declined by 10 percent from 2009 to 2010. Pharmaceutical companies are cutting back mostly in detailing and sampling, while spending in mailings and print advertising grew since last year.
The pharmaceutical sector in the Middle-East and North Africa (MENA) has observed remarkable growth over the last few years and is estimated to reach around US$60 billion by 2025, with US$1.2-billion allocated for the healthcare system in the 2019 budget.
With governments in the region focusing more and more on the well-being of a growing population and enhancing healthcare services, timely and safe delivery of medical supplies and pharmaceuticals products has laid down the promising future for pharmaceutical industry in the region. According to studies, the pharma sector’s growth in the region is largely driven by high population growth, increased life expectancy and the predominance of lifestyle-related diseases such as diabetes, as well as the desire for excellent healthcare services among countries in the region.
Growth opportunities
Promising demographics and increase in life expectancy is shifting the demographic pattern (rising ageing population) and is expected to drive pharmaceutical demand in the Middle-East. During the next 10 years, the share of population that is over 65 years is expected to grow from 2.7% to 4% in overall population.
The Middle-East population growth has averaged over 2.7% per annum. High life expectancy and steep population growth are expected to drive demand for pharmaceuticals in the coming years. Increasing healthcare consciousness and growth in per capita income have created higher healthcare demand. The infant mortality rate has significantly declined over the years due to availability of better healthcare facilities and medication.
Moreover, governments are launching various national health programmes to increase awareness of diseases. For example, the UAE is leading the growth with over US$1.2 billion funneled into the healthcare system in the 2019 budget, on top of substantial funds allotted in the US$540 million innovation fund set up by Sheikh Mohammed bin Rashid Al Maktoum.
Other lifestyle diseases are also rising in the region thus boosting the growth of pharmaceutical firms. The UAE ranks second in the world and first in the Middle-East region for diabetes prevalence (20%), followed regionally by Saudi Arabia (16.7%), Bahrain (15.2%), Kuwait (14.4%), Syria (10.8%), Iraq (10.2%), Jordan (10.1%), Palestine (8.6%), and Lebanon (7.8%). Moreover, obesity related and other coronary diseases are rising in the region. Middle-East generic manufacturers, although excited about the growth prospects of 15% compound annual growth rate, however, face stiff competition with international firms.
One of the decisive phases of the MENA pharma market is the existence of the Gulf Cooperation Council (GCC). The GCC is a multinational partnership consisting of Bahrain, Oman, Saudi Arabia, Kuwait, the UAE and Qatar, who came together in 2014 to establish a drug price harmonisation strategy in order to standardise drug prices within the region. GCC has contributed significantly to the growth of pharmaceutical industry in the region.
Presence of local and global producers
In the Middle-East, Saudi Arabia is the largest pharmaceutical market with 60 per cent of regional share followed by the UAE. Saudi Arabia has the largest manufacturing segment in the Gulf, however, most of the local production is destined for export markets. Domestic production accounts for around 15% of the overall supply of pharmaceuticals in the market. There are around 15-20 pharmaceutical manufacturers operating in the kingdom including indigenous companies and subsidiaries of multinational pharmaceutical giants.
Leading indigenous players in the region include Spimaco, Jamjoom Pharma, Tabuk Pharmaceutical Manufacturing, Jazeera Pharmaceutical Industries and Julphar. The locally-grown companies predominantly make generic drugs, while some also undertake under-license manufacturing on behalf of multinational pharmaceutical companies for supply in the domestic and regional markets. Top multinational companies like GSK, Sanofi and Abbott Laboratories have also set up manufacturing units in the region.
Accelerated drug-registration systems, investments in R&D, innovation, and technological advancement, have led to a rise in the number of international pharmaceutical companies from 30 in 2013 to 47 in 2016, and is expected to reach 75 in 2020. Moreover, around 95% of the global pharmaceutical companies have a base in the UAE, which gives them logistics access to 43 countries worldwide.
Opening of the Dubai Silk Road Strategy and prevailing outstanding logistics infrastructure, the UAE is fast turning into a source market in the supply chain, manufacturing and exporting pharmaceuticals to high-demand markets such as Africa and Asia.
Apart from Saudi Arabia and the UAE, other countries which are fast catching up in terms of demand as well as production are Qatar and Bahrain. The Qatari pharmaceutical industry will benefit from the implementation of the national health insurance program. At the same time, in Bahrain, the government is increasingly encouraging the use of generic medicines among the doctors and patients. The healthcare industry in Bahrain is largely funded by the government contributing around 70% of the total healthcare expenditure every year.
Size and spending of market in MENA
Pharmaceutical spending ranges between 0.36% and 3.47% of GDP and between 11% and 49.3% of health expenditure in the MENA countries. Pharmaceutical spending as a proportion of health expenditure is highest in Lebanon (49.3%), Jordan (33.8%) and Algeria (31.2%).
Likewise, pharmaceutical spending as a proportion of GDP is highest in the same three countries: Lebanon (3.47%), Jordan (2.85%), and Algeria (2.31%). Pharmaceutical spending is lowest as a proportion of GDP or health expenditure in Qatar (0.36% and 11.0%, respectively), the UAE (0.67% and 16.3%, respectively), and Kuwait (0.93% and 18.1%, respectively).
The size of market in terms of total sales has shown an impressive figure of $32 billion across MENA as a whole – the Middle-East accounts for $20.3 billion and North Africa $10.7 billion. Saudi Arabia is the top pharmaceutical market among Middle-East countries according to 2017 sales numbers at $7.5bn and grew at 13% in value terms and 15% in volume terms, with Turkey ($6.9bn), Egypt ($3.4bn) and the UAE ($3.17bn) following closely behind. However, overall the North Africa region is expected to see faster growth rates in the next couple of years at 7.6% CAGR.
While MNCs account for 62% market share growing at 9% previous period growth (PPG); indigeneous companies have grown faster at 19% PPG taking away share from MNC. Firms like Sophal, Dar Al Dawa, Sun Pharma, and Taha Pharma are the fastest growing corporations in Algeria, the UAE, Morocco, and Tunisia respectively. Alimentary tract is the top selling TA (Therapy Area) holding 21% of the market share with the highest growth in Saudi Arabia (12% PPG) and Algeria (12% PPG) followed by Tunisia (9% PPG).
The UAE market is valued at $2.2 billion growing by 12% over last year with retail channel being dominant having 79% share growing at 14% previous growth. Alimentary TA accounts for 24% market share growing at 12% PPG generating additional approximately $51mn in 2018. Multinationals dominate the market in sales with Novartis ($210mn) being the leading player however local players like Julphar ($100mn) feature among top 10 and Dar Al Dawa (78% PPG) is the fastest growing corporation.
Egypt pharma market is valued at $3.4bn with a growth rate of 26% over last year. Alimentary and anti-infectives are the top selling TAs together accounting for 36% sales of the total market. Novartis is the leading corporation with $267mn sales in 2018 while Medical Union Pharma is the fastest growing corporation experiencing a growth rate of 55% over last year.
Morocco market has grown at 12% PPG reaching close to 1.0 bn sales in 2018. Sanofi with $89mn sales is the leading player, GSK’s Augmentin with $17mn sales is the top selling brand and Sun Pharma with 45% PPG is the fastest growing corporation.
The Lebanese market grew at 4.8% PPG, to reach $0.8 bn sales; top 10 corporations comprise 42% of the total sales in Lebanon which include 2 local/regional companies. Alimentary and Cardiovascular are the top 2 TAs together accounting for 37% market share in 2018. GSK’s Panadol leads among top 10 products while MSD’s Zocor and Temodal slowed down at -9%PPG and -8% PPG respectively.
Another part of the Middle-East region that has a strong established pharmaceutical market at the moment is Israel. The market has been projected to grow to $2.12 billion by 2020, at a compound annual growth rate of 3.9%, according to a study by Global Data. Israel already has a strong network of academic and research institutes, R&D facilities and advanced medical facilities. Advancing biotech will likely be a driver of the market in future. Israel’s generics market, which accounts for around 20% of the market sales, is underpinned by Teva, the world’s leading generics manufacturer, which owns several manufacturing and export facilities across Israel, North America and Europe.
Africa:
A growth scenario is the one expected on African pharmaceutical market. The predicted growth in the global pharmaceutical market between 2012 and 2021 is estimated at 26% (according to PROPARCO’s SP & D publication), but the African drug market could increase by 200% according to a realistic assumption, or by 300% according to an optimistic hypothesis within this same period. Based on African Pharmaceuticals Market Report of Frost and Sullivan of 2016, the pharmaceuticals market in Africa is expected to reach a business opportunity of $45 billion in 2020. Goldstein Research analyst forecast the Africa pharmaceuticals market size is set to reach USD 160.7 billion by 2024, at a CAGR of 20.4% over the forecast years.
This rapid growth could be dependent of a convergence of changing economic profiles, rapid urbanisation, increased healthcare spending and investment, and increasing incidence of chronic lifestyle diseases. Major driving factor for Africa pharmaceutical market is the expansion of healthcare capacity which according to the World Bank Africa acquired 70,000 new hospital beds, 16,000 doctors, and 60,000 nurses, adding up to a total of 1,050,000 beds, 498,370 doctors, and 1,250,000 nurses between 2005 and 2012.
African pharmaceutical market scenario
The tropical climate of Africa makes the continent the largest reservoir of infectious diseases, particularly malaria, tuberculosis (TB), and acquired immune deficiency syndrome (AIDS), besides frequent outbreaks of polio, meningitis, cholera, pandemic influenza, yellow fever, measles, hepatitis, and tetanus. With the increasing adoption of Western lifestyle in Africa, there has been a paradigm shift in the burden of illness towards non-communicable diseases (NCDs), driving the demand for chronic prescription drugs. Based on World Health Organization prediction, the proportional contribution of NCDs to the healthcare burden in Africa will rise by 21% through 2030. In the meanwhile, population will continue to suffer from infectious and parasitic illness, but lifestyle diseases such as cardiovascular diseases, diabetes, and cancer will witness high growth rates throughout the forecast period. Limited affordability of governments and the general population for healthcare and pharmaceuticals and a high reliance on donor funding will be the major market restraints.
Market Overview
Half of Africans do not have access to essential drugs. With the provision of the right drugs to treat respiratory infections, diarrheal diseases and malaria, around 10 million lives would have been saved in 2015. Every 30 seconds one African child is killed due to malaria. The 10 largest pharmacy retail chains in Nigeria, Kenya and Ghana manage 186 outlets for a population of almost a quarter of a billion people.
*Graphical representation of the funding (Information should be taken from any sources and prepare graphs by you own, do not copy any graphs from other sites)
List of Nursing Companies
USA Pharma Marketing & Industry Companies:
Seattle's pharmaceutical and biotechnology
Europe Pharma Marketing & Industry Companies:
Teva Pharmaceutical Industries
Asia Pharma Marketing & Industry Companies:
Middle East Pharma Marketing & Industry Companies:
African Pharma Marketing & Industry Companies:
Teva Pharmaceutical Industries
Australia Pharma Marketing & Industry Companies:
List of Pharma Marketing & Industry Universities
USA Pharma Marketing & Industry Universities:
University of Southern California | CUNY York College | Purdue University | University of Wisconsin-Madison | Albany College of Pharmacy and Health Sciences | University of North Carolina | University of Colorado | Oregon State University | Nova Southeastern University | Massachusetts College of Pharmacy and Health Sciences | University of Florida College of Pharmacy | University of Michigan College of Pharmacy | Campbell University School of Pharmacy | University of Pittsburgh School of Pharmacy | University of Georgia College of Pharmacy | Temple University School of Pharmacy | Ernest Mario School of Pharmacy | Skaggs School of Pharmacy | Eugene Applebaum College of Pharmacy and Health Sciences | University of North Carolina | University of Minnesota | University of California—San Francisco | University of Michigan—Ann Arbor | University of Texas—Austin | Ohio State University | University of Illinois—Chicago | University of Kentucky | Purdue University | University of Florida | University of Maryland—Baltimore | University of Pittsburgh | University of Southern California | University of Washington| University of Wisconsin—Madison | University of Arizona | University of Iowa | University of Tennessee Health Science Center | University of Utah | University of Kansas | Virginia Commonwealth University | University at Buffalo | University of Colorado—Denver | Auburn University | University of California—San Diego | University of Oklahoma | Northeastern University |
Europe Pharma Marketing & Industry Universities:
Kingston University |Anglia Ruskin University | Aston University School of Life and Health Sciences | University of Birmingham | University of Brighton | Cardiff University | University of Huddersfield Chemical Sciences | University of Huddersfield Pharmacy | Liverpool John Moores University School of Pharmacy and Biomolecular Sciences | London Metropolitan University | Loughborough University | Newcastle University Northern Institute for Cancer Research | Nottingham Trent University School of Science and Technology | University of Nottingham School of Pharmacy | University of Strathclyde |Pharma Conferences 2019 USA| University of Copenhagen |University of South Wales | University of Bradford | European University Cyprus | University of Groningen | University of Central Lancashire | University of Debrecen |Clinical trials Conferences|Tu Braunschweig University| Marburg University | Greifswald University | Frankfurt University | Freiburg University| Kiel University | Wurzburg University | Fu Berlin University | Lomonosov Moscow State University | Saint-Petersburg State University |Novosibirsk State University
Asia Pharma Marketing & Industry Universities:
University of Tokyo | National University of Singapore | Kyoto University | University of Hong Kong | Peking University | Seoul National University | National Taiwan University | Osaka University | Tsinghua University | Chinese University of Hong Kong | Fudan University |The Hong Kong University of Science and Technology | Taipei Medical University |Mahidol University | Korea Advanced Institute of Science and Technology | Yonsei University |Shanghai Jiao Tong University | Nanyang Technological University | Chulalongkorn University | Tohoku University | Tokyo Medical and Dental University | Kyushu University |Nagoya University | Hokkaido University |Sungkyunkwan University | University of Science and Technology of China | Pohang University of Science and Technology | Korea University | University Malaya | Indian Institute of Science
Africa Pharma Marketing & Industry Universities:
Batna 2 University | University of Kinshasa | University of Lubumbashi | Ahram Canadian University | Alexandria University | British University in Egypt | Cairo University | German University in Cairo | Helwan University | Kafrelsheikh University | Mansoura University | Nahda University | Pharos University in Alexandria | Suez Canal University | Tanta University | Zagazig University | Addis Ababa University | Wollega University | Kwame Nkrumah University of Science and Technology | Kenya Methodist University | Kenyatta University | Elmergib University | University of Benghazi | University of Zawia | University of Misurata | University of Rwanda | Nelson Mandela Metropolitan University | North-West University | Rhodes University | University of KwaZulu | University of Limpopo | University of Pretoria | University of the Western Cape | University of the Witwaters | Ahfad University for Women | University of Khartoum | Omdurman Islamic University | Catholic University of Health and Allied Sciences | Kampala International University | Muhimbili University of Health and Allied Sciences | St. John's University of Tanzania | University of Monastir | Makerere University | Mbarara University of Science and Technology| University of Zambia | Harare Institute of Technology | University of Zimbabwe
Australia Pharma Marketing & Industry Universities:
Charles Darwin University | Charles Sturt University | Curtin University of Technology | Griffith University | James Cook University | La Trobe University | Monash University | Queensland University of Technology | RMIT University | University of Canberra | University of Newcastle | University of Queensland | University of South Australia | University of Sydney | University of Tasmania | University of Technology Sydney | University of Western Australia
Pharma Marketing & Industry Associations & Societies:
Royal Pharmaceutical Society | International Pharmaceutical Federation | International Pharmaceutical Students' Federation | European Association of Employed Community Pharmacists in Europe | European Pharmaceutical Union | Pharmaceutical Group of the European Union | Pharmaceutical Society of Australia | The Pharmacy Guild of Australia | The Society of Hospital Pharmacists of Australia | Canadian Pharmacists Association | Chinese Pharmaceutical Association | Danish Association of Pharmaconomists | Indian Pharmacist Association | Pharmaceutical Society of Ireland | Kuwait Pharmaceutical Association | Pharmaceutical Society Of New Zealand | Norwegian Pharmacy Association | National Pharmacy Association | American Association of Colleges of Pharmacy | American Pharmacists Association | American Society for Pharmacy Law | American Society of Consultant Pharmacists | American Society of Health-System Pharmacists | Professional Compounding Centers of America | American College of Clinical Pharmacy | Canadian Society of Hospital Pharmacists | Pharmaceutical Association of Mauritius | Pakistan Pharmacists Association | Philippine Pharmacists Association | College of Psychiatric and Neurologic Pharmacists
List of Pharma Marketing & Industry Journals:
Journal of Pharmaceutical Sciences | International Journal of Pharmaceutics | The Pharmaceutical Journal | Pharmaceutical Research | European Journal of Pharmaceutics and Biopharmaceutics | Molecular Pharmaceutics | European Journal of Pharmaceutical Sciences | Asian Journal of Pharmaceutics | Journal of Pharmacy and Pharmacology | Indian Journal of Pharmaceutical Sciences | Journal of Pharmacy and Pharmaceutical Sciences | Drug Development and Industrial Pharmacy | Journal of Pharmacy Practice | American Journal of Pharmaceutical Education | International Journal of Drug Development & Research | Journal of Bioequivalence & Bioavailability | Journal of Bioanalysis & Biomedicine | Journal of Pharmacogenomics & Pharmacoproteomics | Journal of Vaccines & Vaccination | Journal of Drug Metabolism & Toxicology | Drug Designing: Open Access | Medicinal & Aromatic Plants | Journal of Biomolecular Research & Therapeutics | Research & Reviews in Pharmacy and Pharmaceutical Sciences | Journal of Molecular Pharmaceutics & Organic Process Research | Journal of Developing Drugs | Journal of Pharmaceutics & Drug Delivery Research | Molecular Enzymology and Drug Targets | Research & Reviews: Journal of Pharmaceutics and Nanotechnology | Journal of Pharmacokinetics & Experimental Therapeutics
Pharma Marketing & Industry Associations & Societies:
Royal Pharmaceutical Society | International Pharmaceutical Federation | International Pharmaceutical Students' Federation | European Association of Employed Community Pharmacists in Europe | European Pharmaceutical Union | Pharmaceutical Group of the European Union | Pharmaceutical Society of Australia | The Pharmacy Guild of Australia | The Society of Hospital Pharmacists of Australia | Canadian Pharmacists Association | Chinese Pharmaceutical Association | Danish Association of Pharmaconomists | Indian Pharmacist Association | Pharmaceutical Society of Ireland | Kuwait Pharmaceutical Association | Pharmaceutical Society Of New Zealand | Norwegian Pharmacy Association | National Pharmacy Association | American Association of Colleges of Pharmacy | American Pharmacists Association | American Society for Pharmacy Law | American Society of Consultant Pharmacists | American Society of Health-System Pharmacists | Professional Compounding Centers of America | American College of Clinical Pharmacy | Canadian Society of Hospital Pharmacists | Pharmaceutical Association of Mauritius | Pakistan Pharmacists Association | Philippine Pharmacists Association | College of Psychiatric and Neurologic Pharmacists.